FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136450> ?p ?o ?g. }

• W4324136450 endingPage "LBA249" @default.
• W4324136450 startingPage "LBA249" @default.
• W4324136450 abstract "LBA249 Background: IMbassador250 was a prospective phase III international trial which showed no overall survival (OS) benefit for adding atezolizumab to enzalutamide for men with mCRPC who had prior progression on abiraterone. We hypothesized that genomic biomarkers in ctDNA may identify patients who have poorer OS with 2 nd generation novel hormonal therapy. Methods: Pre-treatment (but post-abiraterone progression) plasma samples from IMbassador250 were submitted for comprehensive genomic profiling using FoundationOne Liquid CDx. We detected elevated ctDNA tumor fraction (TF) using a novel algorithm that incorporates aneuploidy as well as tumor-derived short variant signal. A pre-specified TF cutoff of ≥ 2% was defined as high. A prospective-retrospective biomarker statistical analysis plan was developed in accordance with Simon Criteria, pre-specifying analyses, cutoffs, and power assessments. Results: 494 baseline plasma specimens were evaluable. The TF high group [371 (74%)] had significantly shorter OS than TF low (median 11.0 vs. 22.1 months, HR 4.3, 95% CI 3.0 – 6.1, p < 0.0001) (primary endpoint). Pre-specified supportive analyses compared the performance to prognosticate OS (concordance [std error]) of baseline PSA alone (0.65 [0.63 – 0.67]) to a model consisting of all evaluable baseline features including PSA, treatment arm, age, race, ECOG score, hemoglobin, alkaline phosphatase, albumin, number of metastatic sites, and sites of metastasis (0.71 [0.70 – 0.73]) to TF alone (0.72 [0.71 – 0.73]) to all features plus TF (0.76 [0.74 – 0.77]). Likelihood ratio test for improvement of OS prediction by adding TF to all available clinical features: p < 0.0001. Focusing on the patients with TF ≥ 2% (n = 371) exploratory analysis observed less favorable outcomes with detection of AR amplifications (n = 203 [55%], HR: 1.4, 95%CI: 1.1 – 1.8), while individual AR mutations were not as strongly associated with OS: L702 ([16%], HR: 1.2, 95%CI: 0.88 – 1.7), W742 ([4.3%], HR: 0.59, 95%CI: 0.30 – 1.2), H875 ([9.4%], HR: 0.71, 95%CI: 0.46 – 1.1), T878 ([25.3%], HR: 0.86, 95%CI: 0.65 – 1.1). Conclusions: In this cohort TF < 2% at baseline is strongly associated with favorable OS on enzalutamide after progression on abiraterone compared to TF ≥ 2%. TF alone has comparable discriminatory ability to anticipate overall survival compared to all available clinical features combined, and adds significant prognostic power when combined with clinical features in this setting. AR amplifications, but not mutations, further improve strengths of association. Clinical trial information: NCT03016312 ." @default.
• W4324136450 created "2023-03-15" @default.
• W4324136450 creator A5001032099 @default.
• W4324136450 creator A5002641296 @default.
• W4324136450 creator A5018153995 @default.
• W4324136450 creator A5025819053 @default.
• W4324136450 creator A5045665778 @default.
• W4324136450 creator A5054079906 @default.
• W4324136450 creator A5072911394 @default.
• W4324136450 creator A5087092015 @default.
• W4324136450 creator A5088131898 @default.
• W4324136450 date "2023-02-20" @default.
• W4324136450 modified "2023-10-18" @default.
• W4324136450 title "Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC." @default.
• W4324136450 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.lba249" @default.
• W4324136450 hasPublicationYear "2023" @default.
• W4324136450 type Work @default.
• W4324136450 citedByCount "0" @default.
• W4324136450 crossrefType "journal-article" @default.
• W4324136450 hasAuthorship W4324136450A5001032099 @default.
• W4324136450 hasAuthorship W4324136450A5002641296 @default.
• W4324136450 hasAuthorship W4324136450A5018153995 @default.
• W4324136450 hasAuthorship W4324136450A5025819053 @default.
• W4324136450 hasAuthorship W4324136450A5045665778 @default.
• W4324136450 hasAuthorship W4324136450A5054079906 @default.
• W4324136450 hasAuthorship W4324136450A5072911394 @default.
• W4324136450 hasAuthorship W4324136450A5087092015 @default.
• W4324136450 hasAuthorship W4324136450A5088131898 @default.
• W4324136450 hasConcept C126322002 @default.
• W4324136450 hasConcept C143998085 @default.
• W4324136450 hasConcept C160798450 @default.
• W4324136450 hasConcept C185592680 @default.
• W4324136450 hasConcept C188816634 @default.
• W4324136450 hasConcept C203092338 @default.
• W4324136450 hasConcept C2781197716 @default.
• W4324136450 hasConcept C535046627 @default.
• W4324136450 hasConcept C55493867 @default.
• W4324136450 hasConcept C71924100 @default.
• W4324136450 hasConceptScore W4324136450C126322002 @default.
• W4324136450 hasConceptScore W4324136450C143998085 @default.
• W4324136450 hasConceptScore W4324136450C160798450 @default.
• W4324136450 hasConceptScore W4324136450C185592680 @default.
• W4324136450 hasConceptScore W4324136450C188816634 @default.
• W4324136450 hasConceptScore W4324136450C203092338 @default.
• W4324136450 hasConceptScore W4324136450C2781197716 @default.
• W4324136450 hasConceptScore W4324136450C535046627 @default.
• W4324136450 hasConceptScore W4324136450C55493867 @default.
• W4324136450 hasConceptScore W4324136450C71924100 @default.
• W4324136450 hasIssue "6_suppl" @default.
• W4324136450 hasLocation W43241364501 @default.
• W4324136450 hasOpenAccess W4324136450 @default.
• W4324136450 hasPrimaryLocation W43241364501 @default.
• W4324136450 hasRelatedWork W2092900223 @default.
• W4324136450 hasRelatedWork W2295722933 @default.
• W4324136450 hasRelatedWork W2515762743 @default.
• W4324136450 hasRelatedWork W2531350361 @default.
• W4324136450 hasRelatedWork W2533581028 @default.
• W4324136450 hasRelatedWork W2768374354 @default.
• W4324136450 hasRelatedWork W3153396815 @default.
• W4324136450 hasRelatedWork W4210755456 @default.
• W4324136450 hasRelatedWork W4225398559 @default.
• W4324136450 hasRelatedWork W4321003452 @default.
• W4324136450 hasVolume "41" @default.
• W4324136450 isParatext "false" @default.
• W4324136450 isRetracted "false" @default.
• W4324136450 workType "article" @default.